SAB Biotherapeutics, Inc.

US$3.03As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:SABSHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (45.97%)
Div yield —
ROE (42.83%)
Biotechnology
Beta (5Y) 0.75
PE TTM —
TSR TTM (6.77%)
Mkt cap US$273.0M
ROIC (27.46%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$3.18
5.09%
(97.76%)
Hold 10|5|10|12|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.06
0.07
0.06
0.06
15.54%
14.36%
6.32%
10.21%
Revenue$M
19.86
20.62
20.51
21.34
12.16%
10.94%
5.95%
9.75%
Peers (US$273.0M)
Cap (US$)
PE
276.8M
5.834x
269.1M
179.9x
Capital
TTM
5Y
10Y
Leveragex
0.418
0.381
0.339
EBIT/Intx
0.671
0.286
0.241
Own earn%
(6.13)
24.95
33.19
Sh yield%
28.99
23.22
22.65
Owners
Insiders/Inst%
12.60
48.51
Short interest%
5.79
SBC / revenue%
5.84
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
22
Op margin range%
8–15
$1 testx
—
Incr. ROIC%
12